by 03-March 2019

The Top 3 Stocks to Watch in March 2019

If you really want to become a better investor then you need to be looking at where the smart money is heading.  You need to understand what is truly driving the markets and how you can take advantage of these moves as – and before – they hit the mainstream.

That’s how the long-term wealth can be found.

In fact, we’ve uncovered three stocks that should have a place in your portfolio immediately.

Opportunity No. 1 – Intec Pharma (NASDAQ:NTEC)

Just this month, the company announced the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion Pill platform containing synthetic tetrahydrocannabinol (THC), one of the primary cannabinoids contained in cannabis.

“We are very pleased to be advancing our medical cannabinoid development program as we believe the Accordion Pill’s gastric retentive technology is ideally suited to extend the absorption phase of THC, with the goal of a slower rate of rise and more consistent drug plasma levels after oral delivery,” said Jeffrey A. Meckler, Vice Chairman and CEO.

“We continue to be enthusiastic about the potential for this program, especially as the U.S. Food and Drug Administration’s recent approval of a cannabinoid product has demonstrated the Agency’s growing recognition of the importance of cannabinoid therapeutics. Given the known analgesic properties of cannabinoids, we expect our AP-cannabinoids will be applicable to a variety of pain indications,”

However, it’s not just the cannabis angle that has us excited.

The company is currently conducting a late stage trial for its long-lasting pill to treat Parkinson’s disease, and expects to start seeing revenue on it this year.  We’re encouraged after Phase II showed a 45% reduction in “daily off time,” which gave patients more than two extra hours a day of movement.  Assuming a 10% market share, Meckler noted, “We have a drug that is worth more than $300 million a year.”

Opportunity No. 2 – Ceragon Networks (NASDAQ:CRNT)

2019 could a big year for 5G investors.

We’re talking about a potential $1.3 billion story that could provide us with speeds up to 100x faster than 4G networks. Speed like that is a game-changer.

When 3G hit, it gave the world access to mobile television and video on demand. As a result, stocks like Broadcom soared more than 240%. Qualcomm jumped more than 260%.

Then 4G hit, and stocks like Crown Castle jumped more than 540%.

Imagine what’ll happen to stocks when technology that’s 100x faster than 4G hits.

Now 5G is Rolling Out

Companies will begin to roll out 5G, or 5th generation mobile networks. The goal is to provide quicker Internet speeds for users. The other objective of 5G is to help usher in the next wave of human-technology interaction, such as with the Internet of Things (IoT) and autonomous cars.

4G has a download speed of 100 megabits per second.

But that’s nothing compared to the 10,000 megabits per second that 5G can handle. That’s 100 times faster than 4G, and would be under significant demand.

By 2035, about $12.3 trillion worth of goods and services will be enabled by 5G networks, and the rollout of 5G will add approximately $3 trillion to the worldwide GDP.

One of the stocks that could benefit is Ceragon Networks – a long-term buy and hold.

Opportunity No. 3 – Aleafia Health Inc. (OTC:ALEAF)

Cannabis is quickly becoming one the most disruptive forces in the world.

So much so, it could disrupt some $500 billion worth of global markets, says Canopy Growth Chairman and CEO, Bruce Linton, who also called that a more “accurate” estimate than “conservative” predictions for $200 billion.

In fact, cannabis’ presence can already be seen in beverages, alcohol, sports drinks, pharmaceuticals, tobacco, and the $4.2 trillion wellness industry are being transformed nearly overnight. As a matter of fact, the healing qualities of cannabis are why spa, wellness and skincare industries are introducing a range of products with cannabis as a key ingredient.

“Hemp-derived CBD has been touted in several medical studies as having a myriad of health benefits ranging from treating psoriasis, atopic dermatitis and eczema to minimizing seizures, stress, and insomnia,” says Forbes.

One of the companies benefiting from the story is ALEAF. 

In Conclusion

If you really want to become a better investor then you need to be looking at where the smart money is heading.  You need to understand what is truly driving the markets and how you can take advantage of these moves as – and before – they hit the mainstream.

That’s how the long-term wealth can be found.


This manual is for informational and entertainment purposes only. The author is not an investment adviser, financial adviser, or broker, and the material contained herein is not intended as investment advice. If you wish to obtain personalized investment advice, you should consult with a Certified Financial Planner (CFP). All statements made in this manual are based on the author’s own opinion. Neither the author or the publisher warrants or assume any responsibility for the accuracy of the statements or information contained in this manual, and specifically disclaims the accuracy of any data, including stock prices and stock performance histories. No mention of a particular security or instrument herein constitutes a recommendation to buy or sell that or any security or instrument, nor does it mean that any particular security, instrument, portfolio of securities, transaction or investment strategy is suitable for any specific individual. Neither the author or the publisher, can assess, verify, or guarantee the accuracy, adequacy, or completeness of any information, the suitability or profitability of any particular investment or methodology, or the potential value of any investment or informational source. READERS BEAR THE SOLE RESPONSIBILITY FOR THEIR OWN INVESTMENT DECISIONS. NEITHER THE AUTHOR OR THE PUBLISHER IS RESPONSIBLE FOR ANY LOSSES DUE TO INVESTMENT DECISIONS MADE BASED ON INFORMATION PROVIDED HEREIN. At the time of writing, neither the author or the publisher has a position in any of the stocks mentioned in this manual.